biocentury.com· BioCentury·· 17 hours agoPickScore76
Limited competition behind Icotyde may help justify Gilead’s $1.3B PepStar deal
In brief
Gilead announced a $1.275 billion upfront payment for worldwide rights to PepStar Therapeutics' oral IL-23R inhibitor program, whose lead candidate HCXT-2001 is a macrocyclic peptide.
Why it matters
Gilead paid $1.275 billion up front for a Phase I macrocyclic peptide lacking clinical efficacy data; the article explains the price via the oral therapy market and scarce competition.
Source: biocentury.com · biocentury.com